Literature DB >> 26260358

In vitro study of cyclosporine A 0.05 % on primary and recurrent pterygium fibroblasts.

Magda Massae Hata Viveiros1,2, Fabiano Yutaka Kakizaki3, Laura Almeida Hércules3, Carlos Roberto Padovani4, João Manuel Grisi Candeias5, Silvana Artioli Schellini3.   

Abstract

To compare the cyclosporine 0.05 % exposure effect on fibroblasts from primary and recurrent pterygium. Primary culture of fibroblasts from primary and recurrent pterygium was performed until the third passage, which was exposed to cyclosporine 0.05 % in a group and the other remaining unexposed (control group), in triplicates. After 3, 6, 12, and 17 days of exposure the viable cell counting was performed by hemocytometer. The results were statistically analyzed using the technique of analysis of non-parametric variance model for repeated measures with three factors. There was a significant reduction in both fibroblast proliferation, in primary as in the recurrent pterygium cultures exposed to cyclosporine when compared not exposed cultures, with statistical significance (P < 0.05). Comparing primary and recurrent pterygium that received the drug, there was no significant difference in cell proliferation in relation to primary or recurrent pterygium. Cyclosporine 0.05 % is effective in inhibiting fibroblast proliferation in culture, both in primary and as in recurrent pterygium.

Entities:  

Keywords:  Cyclosporine; Fibroblasts; In vitro; Pterygium

Mesh:

Substances:

Year:  2015        PMID: 26260358     DOI: 10.1007/s10792-015-0106-2

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  39 in total

Review 1.  Recent developments in drug therapy for aplastic anemia.

Authors:  Lauren Willis; Amber Rexwinkle; Jeffrey Bryan; Tapan M Kadia
Journal:  Ann Pharmacother       Date:  2014-09-02       Impact factor: 3.154

2.  [Conjunctival limbal autograft versus simple excision with intra-operative mitomycin C in pterygium surgery: a comparative study].

Authors:  I Malek; I Zghal; A Chebbi; Z Lajili; C Boujemaa; L Nacef; H Bouguila; S Saida Ayed
Journal:  J Fr Ophtalmol       Date:  2012-12-10       Impact factor: 0.818

3.  Uveitis in Behçet disease in a tertiary center over 25 years: the KKESH Uveitis Survey Study Group.

Authors:  J Fernando Arevalo; Andres F Lasave; Mohanna Yousef Al Jindan; Nasser Abdulmohsen Al Sabaani; Ammar M Al-Mahmood; Yahya A Al-Zahrani; Hassan A Al Dhibi
Journal:  Am J Ophthalmol       Date:  2014-10-22       Impact factor: 5.258

4.  [Cyclosporine A and thiotepa in prevention of postoperative recurrence of pterygium].

Authors:  H Wu; G Chen
Journal:  Yan Ke Xue Bao       Date:  1999-06

5.  Intraoperative subconjunctival bevacizumab as an adjunctive treatment in primary pterygium: a preliminary report.

Authors:  Maha M Shahin; Amal M Elbendary; Mohamed M Elwan
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2012-08-10

6.  Topical cyclosporine A in the prevention of pterygium recurrence.

Authors:  Ozlem Yalcin Tok; Ayse Burcu Nurozler; Gul Ergun; Fatma Akbas Kocaoglu; Sunay Duman
Journal:  Ophthalmologica       Date:  2008-09-01       Impact factor: 3.250

7.  Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis.

Authors:  Neri Pucci; Elio Novembre; Antonella Cianferoni; Enrico Lombardi; Roberto Bernardini; Roberto Caputo; Luciana Campa; Alberto Vierucci
Journal:  Ann Allergy Asthma Immunol       Date:  2002-09       Impact factor: 6.347

8.  Trypan blue exclusion test of cell viability.

Authors:  W Strober
Journal:  Curr Protoc Immunol       Date:  2001-05

9.  [Exposure of normal Tenon's capsule fibroblasts from pterygium to 5-fluorouracil and mitomycin C].

Authors:  Magda Massae Hata Viveiros; Silvana Artioli Schellini; João Candeias; Carlos Roberto Padovani
Journal:  Arq Bras Oftalmol       Date:  2007 Jan-Feb       Impact factor: 0.872

10.  Long-term topical cyclosporin A therapy in Thygeson's superficial punctate keratitis: a case report.

Authors:  Murat Hasanreisoglu; Rahamim Avisar
Journal:  Cases J       Date:  2008-12-23
View more
  5 in total

1.  Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13.

Authors:  Yeoun-Hee Kim; Jae-Chang Jung; Sang Il Gum; Su-Bin Park; Jin Yeul Ma; Yong Il Kim; Kyoo Won Lee; Young Jeung Park
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

2.  The Effect of Topical 0.05% Cyclosporine in the Prevention of Recurrence Following Pterygium Surgery.

Authors:  Ayse Sevgi Karadag; Emre Guler; Emre Guler
Journal:  Beyoglu Eye J       Date:  2021-09-27

3.  PLA-PEG Implant as a Drug Delivery System in Glaucoma Surgery: Experimental Study.

Authors:  Viktoriya N Germanova; Elena V Karlova; Larisa T Volova; Andrey V Zolotarev; Viktoriya V Rossinskaya; Ivan D Zakharov; Aleksandr R Korigodskiy; Violetta V Boltovskaya; Irina F Nefedova; Mariya V Radaykina
Journal:  Polymers (Basel)       Date:  2022-08-21       Impact factor: 4.967

4.  Extracellular matrix and fibroblast injection produces pterygium-like lesion in rabbits.

Authors:  Judith Zavala; Julio C Hernandez-Camarena; Brenda Salvador-Gálvez; José E Pérez-Saucedo; Amin Vela-Martinez; Jorge E Valdez-García
Journal:  Biol Res       Date:  2018-06-05       Impact factor: 5.612

5.  Management of Recurrent Pterygium with Severe Symblepharon Using Mitomycin C, Double Amniotic Membrane Transplantation, Cryopreserved Limbal Allograft, and a Conjunctival Flap.

Authors:  Yu Monden; Chikako Nagashima; Noriko Yokote; Fumi Hotokezaka; Satoshi Maeda; Kensuke Sasaki; Ryoji Yamakawa; Shigeo Yoshida
Journal:  Int Med Case Rep J       Date:  2020-05-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.